The PREVENT trial showed that preventive PCI plus optimal medical therapy was more effective than medical therapy alone for patients with nonflow-limiting vulnerable coronary plaques. The study included 1,606 patients with vulnerable plaque and coronary stenosis greater than 50% but negative fractional flow reserve. Results at 2 and 7 years showed that PCI provided better clinical outcomes, with lower rates of target vessel failure and patient-oriented composite outcomes. These findings suggest a new patient population that may benefit from PCI for nonflow-limiting vulnerable plaques. The study was funded by multiple organizations and the lead author has received research grants and speaker fees.
Source link
PCI may benefit patients with unblocked arteries but vulnerable plaque vs. medical therapy
